North America and Europe PEGylated Drugs Market size is projected to experience significant growth from 2019 to 2025
Owing to the advent of advanced medical therapies and innovative technologies, North America and Europe PEGylated drugs market has witnessed remarkable transformation in the recent years. The massive proliferation of tech breakthroughs in the healthcare and medical devices industry has intensified the competitive landscape of this business space. Numerous firms partaking in North America and Europe PEGylated drugs market have been striving to bring forth a range of high-grade products to effectively treat chronic diseases such as cancer and multiple sclerosis. Consequentially, the unveiling of these progressive medicines and their mainstream utilization across healthcare sector would have an optimistic influence on North America and Europe PEGylated drugs industry in the forthcoming years.
A brief overview of how technological advancements would impel North America and Europe PEGylated drugs industry trends
Citing an instance to affirm the significance of the ongoing innovations across North America and Europe PEGylated drugs industry, the European Commission approved the biopharmaceutical giant Shire’s second line combination therapy, Onivyde, in 2016. Apparently, this has made Onivyde, which basically is a pegylated liposomal irinotecan hydrochloride trihydrate, the first licensed treatment therapy that can be administered to adults with metastatic adenocarcinoma of pancreas. Reportedly, the latest EU license approval follows the U.S. Food and Drug Administration’s (FDA) sanction of the drug, after Shire secured U.S. marketing authorization in October 2015.
Speaking in the similar context, it would be prudent to mention that pancreatic cancer is the seventh leading cause of death across the world and fourth in Europe. For the record, pancreatic cancer causes approximately 330,400 deaths annually throughout the continent, as per reliable estimates. Moreover, poor prognosis and delayed medical intervention has further aggravated the current medical care scenario. However, the prevailing cancer treatment procedures would undergo a revolution of sorts with the arrival of advanced drugs such as Onivyde, which would eventually impact North America and Europe PEGylated drugs market outlook, cite analysts. For the record, cancer application held 60% of the overall North America and Europe PEGylated drugs industry share in 2017.
Get a Sample Copy of this Report @ www.gminsights.com/request-sample/detail/2511
Concurrently, it has been observed that a number of prominent firms are focusing on development and commercialization of targeted therapies to treat rare illnesses. For instance, one of the notable participants in North America and Europe PEGylated drugs industry, Eiger BioPharmaceuticals, Inc recently announced to have received orphan designation by U.S. FDA for its pegylated interferon lambda 1a. The Orphan Drug Designation Program provides orphan status to biologics and drugs which have been defined as safe for diagnosing, treating or preventing rare illnesses that affect less than 200,000 residents of the U.S.
As has been reported, the latest drug by Eiger is being termed as an effective potential treatment for chronic hepatitis delta virus (HDV) infection. Moreover, Lambda is said to be a first in class, well-characterized, late stage, type III interferon that stimulates immune responses which are considered critical for generating host protection from viral infections.
For the record, hepatitis delta is considered as one of the most severe forms of viral hepatitis in humans and is caused by infection with HDV. With a significant impact on global health, hepatitis delta, as per reliable estimates, affects about 15-20 million people worldwide. Therefore, the launch of Eiger’s Lambda is anticipated to predominantly assist healthcare providers in lowering the mortality rates caused by hepatitis delta. This would eventually propel the commercialization potential of North America and Europe PEGylated drugs market over the ensuing years from hepatitis treatment application. The segment accounted for a revenue of USD 156 million in 2017.
With the swift advances being made in developing antibody drug conjugates, immunotherapies, cell therapies, and gene therapies, North America and Europe PEGylated drugs industry is projected to tread along a lucrative growth path. In addition to this, the rising acceptance of biologics drugs, including interferons, colony stimulating factors, and monoclonal antibodies, to treat chronic diseases would further boost the overall growth potential of this business space. In fact, as per a research report compiled by Global Market Insights, Inc., North America and Europe PEGylated drugs market share is estimated to surpass USD 10.5 billion by 2024.
Browse Report Summary @ www.gminsights.com/industry-analysis/north-america-and-eu...
North America & Europe PEGylated drugs market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2013 to 2024, for the following segments:
North America & Europe PEGylated Drugs Market by Disease Indication
o Multiple sclerosis
o Gastrointestinal disorders
North America & Europe PEGylated Drugs Market by Type
o Monoclonal antibodies (mAbs)
o Colony stimulating factors
The above information is provided for the following regions and countries:
• North America
Related Reports @ www.marketwatch.com/press-release/dermatology-devices-mar...
Corporate Sales, USA
Global Market Insights, Inc.
Toll Free: 1-888-689-0688
About Global Market Insights:
Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release North America and Europe PEGylated Drugs Market size is projected to experience significant growth from 2019 to 2025 here
News-ID: 1800825 • Views: 76
More Releases from Global Market Insights Inc.
North America Machine learning as a service market size to witness significant C …
Global Market Insights adds global Machine Learning as a Service Market report which focuses on the major drivers and restraints for the key players. It also provides analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. Request for an in-depth table of contents for this report @ https://www.gminsights.com/request-toc/upcoming/2213 North America dominates the machine learning as a service market owing to high demand for integrating machine learning with
What’s driving the text analytics market report?
Text Analytics Market report gives attention to market segmentation, market size, and forecast of 2019-2025 to help stakeholders in making a good decision for the future investments. The industry report segmented into types, application, and regions with providing production, revenue, import/export. North America holds a major share of the text analytics market owing to availability of advanced IT infrastructure in the region coupled with a thriving e-commerce industry. With rapid adoption
Mobile video surveillance market 2019: Evolving Technology, Trends and Industry …
Mobile video surveillance market report gives attention to market segmentation, market size, and forecast of 2019-2025 to help stakeholders in making a good decision for the future investments. The industry report segmented into types, application, and regions with providing production, revenue, import/export. Request for an in-depth table of contents for this report @ https://www.gminsights.com/request-toc/upcoming/2269 North America mobile video surveillance market is predicted to grow significantly during the forecast timespan. This growth can be
Global cybersecurity market Likely to Emerge over a Period of 2019 – 2024
The North America region is leading the cybersecurity market with over 40% share in 2017. The increasing investments and acquisition of cybersecurity start-ups by major players in the region are adding to market growth. The European region accounted for over 20% market share of the cybersecurity market in 2017. The rising public-private partnerships and government investments are driving the cybersecurity market in the region. The government has also enforced various
More Releases for Europe
Europe Radiotherapy Market
The Europe Radiotherapy Market research report consists of a primary and secondary research along with an in-depth analysis of the quantitative and qualitative aspects by the expert industry analysts and professionals, leading management bodies, to gain a profound insight of the industry as well as the industry performance. The Europe Radiotherapy Market report presents a lucid picture of the current industry landscape, including the historical and projected market size, based